In a regulatory filing, Allergan made a statement in response to inquiries regarding Appaloosa’s press release: “Allergan’s Board of Directors has received Appaloosa’s proposal and is committed to continuing to engage with them, as we do any shareholder who has input and constructive ideas. The Board of Directors is committed to strong governance practices and independent board leadership. The company has been executing its strategy to drive growth and value for shareholders as it transforms into a global biopharmaceutical leader. Allergan has a strong long-term outlook across its four key therapeutics areas and a highly promising R&D pipeline.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.